Keywords: Gene Therapy, Cell Therapy, randomization
In this presentation, we will talk about statistical issues in the Biological Licensure Application review of KYMRIAH, which is the first FDA approved CAR-T therapy. In addition, we will talk about statistical issues related to the timing of randomization in gene and cell therapy trials, based on INDs we have reviewed.